A new candidate vaccine for human brucellosis based on influenza viral vectors: a preliminary investigation for the development of an immunization schedule in a guinea pig model

Table 2 Rates of protection in guinea pigs after challenge with the virulent strain B. melitensis 16 M

Immunization group (prime-boost)	Total animals	Isolation of B. melitensis in animals, n (%)	Value (P)^a
Immunization group (prime-boost)	Total animals	Isolation of B. melitensis in animals, n (%)	( +) control^b	(−) control^c
Vector vaccine at dose of 10⁵ EID₅₀	5	2 (40)	> 0.05	> 0.05
Vector vaccine at dose of 10⁶ EID₅₀	5	1 (20)	> 0.05	< 0.05
Vector vaccine at dose of 10⁷ EID₅₀	5	1 (20)	> 0.05	< 0.05
B. melitensis Rev.1	5	1 (20)	-	< 0.05
Control (PBS)	5	5 (100)	< 0.05	-

^aIn comparison with control untreated PBS or B. melitensis Rev.1 groups
^bAnimals immunized with B. melitensis Rev.1 vaccine
^cAnimals inoculated with PBS. EID₅₀ 50 percent embryo infectious dose
Guinea pigs were immunized twice intranasally 21 days apart with a new vaccine candidate at dose 10⁵ EID₅₀, 10⁶ EID₅₀ and 10⁷ EID₅₀ or a single delivery of the vaccine B. melitensis Rev.1. via s.c. immunization. Animals challenged with virulent strain of B. melitensis 16 M at a dose of 1.3 log₁₀ CFU/animal using subcutaneous route. Statistical analysis was performed using a one-sided Fisher’s exact test. P-value less than 0.05 (< 0.05), P-value higher than 0.05 (> 0.05)

ISSN: 2049-9957